反応式
Cl[CH2:2][C:3]1[O:7][C:6]([C:8]2[CH:13]=[CH:12][C:11]([C:14]3[C:19]([CH3:20])=[CH:18][CH:17]=[C:16]([C:21]([NH:23][CH:24]4[CH2:26][CH2:25]4)=[O:22])[CH:15]=3)=[CH:10][CH:9]=2)=[N:5][N:4]=1.[I-].[K+].C[N:30]([CH:32]=O)C>C1(N)CCCCC1>[CH:32]1([NH:30][CH2:2][C:3]2[O:7][C:6]([C:8]3[CH:13]=[CH:12][C:11]([C:14]4[C:19]([CH3:20])=[CH:18][CH:17]=[C:16]([C:21]([NH:23][CH:24]5[CH2:26][CH2:25]5)=[O:22])[CH:15]=4)=[CH:10][CH:9]=3)=[N:5][N:4]=2)[CH2:12][CH2:13][CH2:8][CH2:9][CH2:10]1参加物
5
反応物 3
生成物 1
試薬・触媒・溶媒 1
実験手順
4′-[5-(Chloromethyl)-1,3,4-oxadiazol-2-yl]-N-cyclopropyl-6-methyl-1,1′-biphenyl-3-carboxamide (Intermediate 45) (37 mg) and potassium iodide (5 mg) were mixed in cyclohexylamine (2 ml) and DMF (2 ml) and the reaction stirred at room temperature for 18 hours. The solvents were evaporated under vacuum and the residue purified by bond-elut (silica), eluting with an ethyl acetate/cyclohexane gradient. After evaporation of the solvent this gave 4′-{5-[(cyclohexylamino)methyl]-1,3,4-oxadiazol-2-yl}-N-cyclopropyl-6-methyl-1,1′-biphenyl-3-carboxamide.
後処理
- customThe solvents were evaporated under vacuum
- customthe residue purified by bond-elut (silica)
- washeluting with an ethyl acetate/cyclohexane gradient
- customAfter evaporation of the solvent this gave 4′-{5-[(cyclohexylamino)methyl]-1,3,4-oxadiazol-2-yl}-N-cyclopropyl-6-methyl-1,1′-biphenyl-3-carboxamide
出典と根拠
- ORDレコード
- ord-21f57a3f9b32472986eedf07d12ae035
- 出典データセット
- uspto-grants-2008_09
- 特許番号
- US07425555B2
関連ノート
読み込み中…